Apolipoprotein E Genotyping
 
OVERVIEW:
 
This test determines an individual’s genetic risk associated with the Apolipoprotein E gene. ApoE is involved in the metabolism of cholesterol and triglycerides, and variants in this gene can have clinically relevant implications for disease risk as well as one’s response to statin therapy, dietary fat, and other risk factors (eg., smoking and alcohol consumption). Approximately 45% of individuals carry one or more of the high risk variants within the ApoE gene. The results of the genotyping of Apolipoprotein E have important implications in the treatment strategies for individual patients in reducing cardiovascular disease risk.
 
Results are typically available within 7-10 business days.
Reports are delivered via general mail or electronically. 
*HIPAA aware: Electronic delivery system is completely confidential and secure.